NCT02258074View on ClinicalTrials.gov

The COMBINE Study: The CKD Optimal Management With BInders and NicotinamidE

PHASE2CompletedINTERVENTIONAL
Enrollment

205

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

November 30, 2018

Study Completion Date

September 30, 2019

Conditions
Chronic Kidney Disease
Interventions
DRUG

Nicotinamide

DRUG

Lanthanum Carbonate

DRUG

Placebo (for Nicotinamide)

Sugar pill manufactured to mimic Nicotinamide 750 mg capsule

DRUG

Placebo (for lanthanum carbonate)

Sugar pill manufactured to mimic Lanthanum Carbonate 500 mg capsule

Trial Locations (7)

20037

George Washington University, Washington D.C.

60201

NorthShore University Health System, Chicago

60611

Northwestern University, Chicago

80230

Denver Nephrology Research, Denver

84112

University of Utah, Salt Lake City

Utah VA, Salt Lake City

92161

University of California at San Diego, San Diego

All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

The Cleveland Clinic

OTHER

NCT02258074 - The COMBINE Study: The CKD Optimal Management With BInders and NicotinamidE | Biotech Hunter | Biotech Hunter